Cargando…

Histone Deacetylase (HDAC) Inhibitors for the Treatment of Schistosomiasis

Schistosomiasis is a major neglected parasitic disease that affects more than 240 million people worldwide and for which the control strategy consists of mass treatment with the only available drug, praziquantel. Schistosomes display morphologically distinct stages during their life cycle and the tr...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ghazy, Ehab, Abdelsalam, Mohamed, Robaa, Dina, Pierce, Raymond J., Sippl, Wolfgang
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2022
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8779837/ https://www.ncbi.nlm.nih.gov/pubmed/35056137 http://dx.doi.org/10.3390/ph15010080

Ejemplares similares

Binding Free Energy (BFE) Calculations and Quantitative Structure–Activity Relationship (QSAR) Analysis of Schistosoma mansoni Histone Deacetylase 8 (smHDAC8) Inhibitors
por: Simoben, Conrad V., et al.
Publicado: (2021)

Docking, Binding Free Energy Calculations and In Vitro Characterization of Pyrazine Linked 2-Aminobenzamides as Novel Class I Histone Deacetylase (HDAC) Inhibitors
por: Bülbül, Emre F., et al.
Publicado: (2022)

The potential for histone deacetylase (HDAC) inhibitors as cestocidal drugs
por: Vaca, Hugo Rolando, et al.
Publicado: (2021)

Design, Synthesis and Biological Characterization of Histone Deacetylase 8 (HDAC8) Proteolysis Targeting Chimeras (PROTACs) with Anti-Neuroblastoma Activity
por: Darwish, Salma, et al.
Publicado: (2022)

A Novel Class of Schistosoma mansoni Histone Deacetylase 8 (HDAC8) Inhibitors Identified by Structure-Based Virtual Screening and In Vitro Testing
por: Simoben, Conrad V., et al.
Publicado: (2018)

Synthesis, Molecular Docking and Biological Characterization of Pyrazine Linked 2-Aminobenzamides as New Class I Selective Histone Deacetylase (HDAC) Inhibitors with Anti-Leukemic Activity
por: Ibrahim, Hany S., et al.
Publicado: (2021)

The Role of Dietary Histone Deacetylases (HDACs) Inhibitors in Health and Disease
por: Bassett, Shalome A., et al.
Publicado: (2014)

Exploring aromatic cage flexibility of the histone methyllysine reader protein Spindlin1 and its impact on binding mode prediction: an in silico study
por: Luise, Chiara, et al.
Publicado: (2021)

Histone deacetylase (HDAC) inhibitors in recent clinical trials for cancer therapy
por: Wagner, Julia M., et al.
Publicado: (2010)

Structure-Based Inhibitor Discovery of Class I Histone Deacetylases (HDACs)
por: Luo, Yuxiang, et al.
Publicado: (2020)

Application of Ligand- and Structure-Based Prediction Models for the Design of Alkylhydrazide-Based HDAC3 Inhibitors as Novel Anti-Cancer Compounds
por: Bülbül, Emre F., et al.
Publicado: (2023)

Histone Deacetylase Inhibitors, Intrinsic and Extrinsic Apoptotic Pathways, and Epigenetic Alterations of Histone Deacetylases (HDACs) in Hepatocellular Carcinoma
por: Sanaei, Masumeh, et al.
Publicado: (2021)

Histone Deacetylase (HDAC) Inhibitors: A Promising Weapon to Tackle Therapy Resistance in Melanoma
por: Palamaris, Kostas, et al.
Publicado: (2022)

Structural Basis for the Inhibition of Histone Deacetylase 8 (HDAC8), a Key Epigenetic Player in the Blood Fluke Schistosoma mansoni
por: Marek, Martin, et al.
Publicado: (2013)

Induction of histone deacetylases (HDACs) in human abdominal aortic aneurysm: therapeutic potential of HDAC inhibitors
por: Galán, María, et al.
Publicado: (2016)

Developing selective histone deacetylases (HDACs) inhibitors through ebselen and analogs
por: Wang, Yuren, et al.
Publicado: (2017)

Transcription Regulation by Class III Histone Deacetylases (HDACs)—Sirtuins
por: Dai, Yan, et al.
Publicado: (2008)

Histone Deacetylases (HDACs) Guided Novel Therapies for T-cell lymphomas
por: Zhang, Qing, et al.
Publicado: (2019)

Harnessing the HDAC–histone deacetylase enzymes, inhibitors and how these can be utilised in tissue engineering
por: Lawlor, Liam, et al.
Publicado: (2019)

Kinetically selective inhibitors of histone deacetylase 2 (HDAC2) as cognition enhancers
por: Wagner, F. F., et al.
Publicado: (2015)

Optimization of Resveratrol Used as a Scaffold to Design Histone Deacetylase (HDAC-1 and HDAC-2) Inhibitors
por: Urias, Beatriz Silva, et al.
Publicado: (2022)

Epigenetic modulation with oral histone deacetylase (HDAC) inhibitor as a new treatment option in JIA
por: Vojinovic, J, et al.
Publicado: (2011)

Regulating the Regulators: The Role of Histone Deacetylase 1 (HDAC1) in Erythropoiesis
por: Kim, Min Young, et al.
Publicado: (2020)

Hydroxyl Ketone-Based Histone Deacetylase Inhibitors To Gain Insight into Class I HDAC Selectivity versus That of HDAC6
por: Traoré, Mohamed D. M., et al.
Publicado: (2017)

NOXA Accentuates Apoptosis Induction by a Novel Histone Deacetylase Inhibitor
por: Ashry, Ramy, et al.
Publicado: (2023)

Histone deacetylase 8 interacts with the GTPase SmRho1 in Schistosoma mansoni
por: Pagliazzo, Lucile, et al.
Publicado: (2021)

Histone Deacetylases and Histone Deacetylase Inhibitors in Neuroblastoma
por: Phimmachanh, Monica, et al.
Publicado: (2020)

CD4(+) T cell lineage integrity is controlled by the histone deacetylases HDAC1 and HDAC2
por: Boucheron, Nicole, et al.
Publicado: (2014)

Critical Functions of Histone Deacetylases (HDACs) in Modulating Inflammation Associated with Cardiovascular Diseases
por: Kulthinee, Supaporn, et al.
Publicado: (2022)

Inhibition of BET Proteins and Histone Deacetylase (HDACs): Crossing Roads in Cancer Therapy
por: Manzotti, Gloria, et al.
Publicado: (2019)

Histone Deacetylases (HDACs): Evolution, Specificity, Role in Transcriptional Complexes, and Pharmacological Actionability
por: Milazzo, Giorgio, et al.
Publicado: (2020)

Balancing Histone Deacetylase (HDAC) Inhibition and Drug‐likeness: Biological and Physicochemical Evaluation of Class I Selective HDAC Inhibitors
por: Schäker‐Hübner, Linda, et al.
Publicado: (2022)

Butyrate Histone Deacetylase Inhibitors
por: Steliou, Kosta, et al.
Publicado: (2012)

Class I histone deacetylases (HDAC1–3) are histone lysine delactylases
por: Moreno-Yruela, Carlos, et al.
Publicado: (2022)

Activity of bromodomain protein inhibitors/binders against asexual-stage Plasmodium falciparum parasites
por: Chua, Ming Jang, et al.
Publicado: (2018)

Expression of Histone Deacetylases HDAC1, HDAC2, HDAC3, and HDAC6 in Invasive Ductal Carcinomas of the Breast
por: Seo, Jinwon, et al.
Publicado: (2014)

Histone Deacetylases and Histone Deacetylase Inhibitors: Molecular Mechanisms of Action in Various Cancers
por: Sanaei, Masumeh, et al.
Publicado: (2019)

Clinical Toxicities of Histone Deacetylase Inhibitors
por: Subramanian, Srividya, et al.
Publicado: (2010)

Histone deacetylases (HDACs) in XPC gene silencing and bladder cancer
por: Xu, Xiaoxin S, et al.
Publicado: (2011)

Histone Deacetylases (HDACs) and Atherosclerosis: A Mechanistic and Pharmacological Review
por: Chen, Xiaona, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_2opk1k43ssrdj4fp5vn1mi5fud